Glioblastoma (GBM), recognized as one of the most aggressive and fatal brain cancers, continues to present formidable challenges for effective treatment. Despite advancements in medical science, immunotherapy—a potent strategy that has revolutionized cancer treatment elsewhere—has yet to demonstrate significant efficacy in combating this malignancy. The overarching difficulty lies in GBM’s ability to evade immune detection, creating an immunologically “cold” tumor microenvironment that resists immune cell infiltration and activation. Emerging research from The University of Texas MD Anderson Cancer Center, published in Nature Communications, unveils a promising dual-targeting approach that may alter this grim landscape by enhancing immunotherapy responsiveness through simultaneous blockage of two critical immune evasion signals.
Cancer cells, including those in glioblastomas, have evolved sophisticated mechanisms to escape immune surveillance. Central to these defenses are what scientists term “don’t eat me” signals—molecular cues expressed on tumor cells that inhibit the engulfing and destruction capabilities of immune cells called macrophages. Macrophages are innate immune effectors known for their role as first responders; they patrol tissues to identify and phagocytose pathogens and abnormal cells. Under typical conditions, these cells also support adaptive immunity by processing tumor-derived antigens and presenting them to T cells, effectively educating these cytotoxic lymphocytes to recognize and eradicate malignant cells.
One well-characterized “don’t eat me” signal is the protein CD47, commonly upregulated in various cancers. CD47 interacts with the macrophage receptor SIRPα, delivering a powerful inhibitory signal preventing phagocytosis. This protective mechanism is essential for healthy cells to avoid unwarranted removal by the immune system, but cancer cells exploit this pathway to cloak themselves against immune attack. Although interventions targeting the CD47-SIRPα axis have shown promise in hematologic malignancies, their effectiveness in solid tumors such as GBM remains limited, underscoring the necessity for alternative or complementary strategies.
Intriguingly, the MD Anderson team has identified another critical immune checkpoint molecule, CD24, which operates similarly by functioning as a “don’t eat me” signal and is abundantly expressed on glioblastoma cells. CD24 interacts with the immune receptor Siglec-10 on macrophages, further impeding their capacity to engulf tumor cells. The redundancy of these immune evasion pathways suggests that targeting CD47 alone may be insufficient to unlock the full potential of the innate immune response against GBM. This discovery prompted an investigation into the combined blockade of both CD47 and CD24 to synergize and amplify immune-mediated tumor clearance.
The experimental approach implemented dual inhibition of these two signaling pathways alongside standard immunotherapeutic agents in preclinical glioblastoma models. Results demonstrated a significantly enhanced anti-tumor effect compared to monotherapies targeting either CD47 or CD24 alone. Macrophages, liberated from the inhibitory constraints imposed by both signals, exhibited substantially increased phagocytic activity, leading to elevated tumor cell clearance. Subsequently, this heightened activity facilitated the presentation of tumor antigens to T cells, catalyzing a robust adaptive immune response capable of eradicating malignancy more effectively.
This novel combination strategy addresses a fundamental issue in GBM treatment: the immune system’s failure to recognize and mount an effective assault on glioblastoma cells. By simultaneously disabling two independent “don’t eat me” signals, the immune system’s front-line defenders—macrophages—not only clear cancer cells more efficiently but also stimulate downstream T cell responses critical for sustained tumor suppression. This dual blockade approach effectively removes the “invisibility cloak” that tumor cells employ, thereby unmasking the cancer to the immune system.
Dr. Wen Jiang, associate professor of Radiation Oncology at MD Anderson, emphasizes the concept of this “one-two punch,” wherein blocking both CD47 and CD24 unleashes a synergistic immune activation far greater than targeting a single pathway. She refers to it as dismantling the tumor’s stealth tactics, reinvigorating immune surveillance by empowering macrophages to act decisively. This layered defense dismantling holds promise not only for GBM but potentially for other solid tumors with similar immune evasion mechanisms.
Further insights from Dr. Betty Kim, professor of Neurosurgery and an integral member of the James P. Allison Institute™, underscore the adaptability and complexity of cancer. Tumors employ multiple, often overlapping, strategies to thwart immune destruction, necessitating multi-targeted approaches to overcome their resilience. She stresses that the redundancy of immune evasion pathways in glioblastoma challenges single-agent immunotherapies, underscoring why combined blockade may initiate a more potent, sustained antitumor immune response.
While these findings herald an exciting therapeutic avenue, translation into clinical application requires additional research. Several CD47 antagonists are currently in clinical trials for various cancers, illustrating a wave of momentum in this field. However, therapeutic agents targeting CD24 remain in nascent stages of development. The path forward includes refining these therapies, evaluating their safety and efficacy in combination, and identifying patient populations poised to benefit most from this immunomodulatory strategy.
The implications of this study extend beyond glioblastoma, shedding light on innate immune-driven therapies leveraging macrophages’ critical role within the tumor microenvironment. It marks a paradigm shift, emphasizing that successful immunotherapy may demand not only activation of T cells but also strategic modulation of macrophages and other innate immune components. This comprehensive immune engagement addresses tumor heterogeneity and evasion multiple axes, potentially overcoming resistance mechanisms that have hampered immunotherapy in tough-to-treat cancers.
Supported by prominent institutions such as the National Institutes of Health, the American Cancer Society, and the Cancer Prevention and Research Institute of Texas, this research represents a collaborative effort aimed at redefining cancer immunotherapy frameworks. By dissecting the molecular interplay governing tumor immunity and resistance, the investigators have taken a decisive step toward novel therapeutic strategies that harness the full armamentarium of the immune system.
As the oncology community eagerly anticipates the development of effective CD24 inhibitors, the current work invigorates hope for patients afflicted with glioblastoma—disease for which therapeutic options and survival rates remain dishearteningly limited. Targeting the sophisticated immune evasion employed by GBM with these dual blockade strategies may unlock previously inaccessible avenues for durable tumor control and improved patient outcomes.
Ultimately, this research exemplifies the quintessential intersection of fundamental immunology and translational medicine, crafting innovative interventions from detailed mechanistic insights. While much work remains, the concept of simultaneously “unmasking” cancer cells by disabling multiple “don’t eat me” signals may well define the next frontier in immunotherapy for glioblastoma and beyond, reinvigorating the fight against this devastating disease.
Subject of Research: Immune evasion mechanisms in glioblastoma and enhancement of immunotherapy through dual blockade of CD47 and CD24 “don’t eat me” signals.
Article Title: Dual Blockade of CD47 and CD24 Reinvigorates Macrophage-Mediated Immunity to Enhance Immunotherapy in Glioblastoma Models.
News Publication Date: March 11, 2026.
Web References:
MD Anderson Cancer Center: https://www.mdanderson.org/
Immunotherapy Overview: https://www.mdanderson.org/treatment-options/immunotherapy.html
Glioblastoma Information: https://www.mdanderson.org/cancer-types/glioblastoma.html
Published Study in Nature Communications: https://www.nature.com/articles/s41467-026-70221-9
References: Wen Jiang, M.D., Ph.D., Betty Kim, M.D., Ph.D., et al. “Dual blockade of CD47 and CD24 enhances macrophage-mediated phagocytosis and immunotherapy response in glioblastoma,” Nature Communications, 2026.
Keywords: Glioblastoma, Immunotherapy, Macrophages, Phagocytosis, CD47, CD24, Immune evasion, Tumor microenvironment, Cancer immunotherapy, Solid tumors, Antigen presentation, Innate immunity.
Tags: cancer cell “don’t eat me” signalsdual-targeting cancer treatmentenhancing immunotherapy responsivenessglioblastoma immune suppressionglioblastoma immunotherapyimmune checkpoint blockade glioblastomaimmune evasion in glioblastomainnate immune response in tumorsmacrophage activation in cancer therapymacrophage-mediated tumor clearanceMD Anderson glioblastoma researchtumor microenvironment in brain cancer
